This study aims to evaluate the impact of tumor location on key molecular alterations on a single voxel level in patients with newly-diagnosed glioma.
A consecutive series of n=237 patients with newly diagnosed glioblastoma and n=131 patients with lower-grade glioma was analyzed. Volumetric tumor segmentation was performed on preoperative MRI with a semi-automated approach and images were registered to the standard Montreal Neurological Institute-152 space. Using a voxel-based lesion-symptom mapping (VSLM) analysis, we identified specific brain regions that were associated with tumor-specific molecular alterations. We assessed a predefined set of n=17 molecular characteristics in the glioblastoma cohort and n=2 molecular characteristics in the lower-grade glioma cohort. Permutation adjustment (n=1000 iterations) was used to correct for multiple testing and voxel t-values that were greater than the t-value in >95% of the permutations were retained in the VLSM results (α=0.05, power >0.8).
Tumor location predilection for isocitrate dehydrogenase (IDH)-mutant tumors was found in both glioblastoma and lower-grade glioma cohorts, each showing a concordant predominance in the frontal lobe adjacent to the rostral extension of the lateral ventricles (permutation-adjusted p=0.021 for the glioblastoma and 0.013 for the lower-grade glioma cohort). Apart from that, the VLSM analysis did not reveal a significant association of the tumor location with any other key molecular alteration in both cohorts (permutation-adjusted p>0.05, each).
Our study highlights the unique properties of IDH-mutations and underpins the hypothesis that the rostral extension of the lateral ventricles is a potential location for the cell of origin in IDH-mutant gliomas.
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 August 2018.
All research outputs
#20,529,980
of 23,099,576 outputs
Outputs from Neuro-Oncology
#2,837
of 3,272 outputs
Outputs of similar age
#289,155
of 331,387 outputs
Outputs of similar age from Neuro-Oncology
#32
of 66 outputs
Altmetric has tracked 23,099,576 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,272 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,387 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 66 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
